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We identified a strain of Actinomyces ruminicola which produces a potent bacteriocin with 16 
activity against a broad range of Gram-positive bacteria – many of which are pathogenic to 17 
animals and humans. The bacteriocin was purified and found to have a mass of 4091+/-1 Da 18 
with a sequence of GFGCNLITSNPYQCSNHCKSVGYRGGYCKLRTVCTCY containing 3 19 
disulphide bridges. Surprisingly, near relatives of actifensin were found to be a series of 20 
related eukaryotic defensins displaying greater than 50% identity to the bacteriocin. A 21 
pangenomic screen further revealed that production of actifensin-related bacteriocins is a 22 
common trait within the genus with 47 being present in 161 genomes.  Furthermore, these 23 
bacteriocins displayed a remarkable level of diversity with a mean amino acid identity of only 24 
52% between strains/species.  This level of redundancy suggests that this new class of 25 
bacteriocins may provide a very broad structural basis on which to deliver and design new 26 
broad-spectrum antimicrobials for treatment of animal and human infections. 27 
Importance 28 
Bacteriocins (ribosomally produced antimicrobial peptides) are potential alternatives to 29 
current antimicrobials given the global challenge of antimicrobial resistance. We identified a 30 
novel bacteriocin from Actinomyces ruminicola with no previously characterised 31 
antimicrobial activity. Using publicly available genomic data we found a highly conserved 32 
yet divergent family of previously unidentified homologous peptide sequences within the 33 
genus Actinomyces with striking similarity to eukaryotic defensins. These actifensins may 34 
provide a potent line of antimicrobial defence/offence and the machinery to produce them 35 
could be used for design of new antimicrobials given the degeneracy that exists naturally in 36 
their structure.  37 
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Introduction 40 
Novel antimicrobial compounds are increasingly important in the food, agriculture 41 
and medical fields due to decreasing efficacies of current antimicrobial treatments. 42 
Bacteriocins are ribosomally-synthesised antimicrobial peptides produced by bacteria which 43 
can target another bacterium of the same species (narrow spectrum) or bacteria of other 44 
species/genera (broad spectrum) (1). Bacteriocin producers are self-protected through the 45 
production of specific immunity proteins, and as bacteriocins are gene encoded, they can be 46 
genetically modified. Bacteriocins produced by Gram positive bacteria have been grouped 47 
according to their primary structure into class I (post-translationally modified bacteriocins) 48 
and class II (unmodified or cyclic bacteriocins) (2). Class II is split into several subgroups, 49 
including the class IId bacteriocins, which are a heterogenous group of linear, unmodified, 50 
non-pediocin like peptides (3).   51 
 . Defensins are antimicrobial peptides ubiquitous among eukaryotes which play a role 52 
in innate immunity but have also been found to act as signalling peptides, toxins, enzyme 53 
inhibitors, abiotic stress responders, and to have anti-cancer properties. Defensins are small 54 
(<10 kDa), cysteine rich (forming three to six disulphide bonds) peptides with low amino 55 
acid identity and the two superfamilies are thought to have evolved convergently (4). Only 56 
two expressed defensin-like bacteriocins have been described; the laterosporulins have been 57 
previously identified among prokaryotes and contain disulphide bonds in positions 58 
homologous to eukaryotic defensins (5, 6).  Other disulphide bond-containing bacteriocins, 59 
such as bactofencin have been compared with eukaryotic defensins due to their highly 60 















cationic nature (7, 8). Laterosporulin, and its homolog Laterosporulin10 are class IId 61 
bacteriocins produced by Brevibacillus spp. which have been described as broad-spectrum 62 
antimicrobials against both Gram negative and Gram positive bacteria. The two peptides are 63 
5.6 kDa and 6.0 kDa and share only 57.6 % amino acid sequence identity but have conserved 64 
cysteines which are characteristic of eukaryotic defensins (6).  65 
Actinomyces spp. are a heterogenous group of high GC content, Gram positive non 66 
spore-forming facultative or obligate anaerobes that belong to the Actinomycetaceae family 67 
within the phylum Actinobacteria (9). In humans, a number of species are known colonisers 68 
of hard surfaces in the oral cavity where they play a key role in plaque biofilm formation (10, 69 
11). They have been identified as core members of the oral bacteriome, present in moderate 70 
abundance (>0.1 - >2.0%) among geographically-diverse populations (10, 12-15). 71 
Actinomyces spp. have been implicated in oral health as being associated in greater 72 
abundance in individuals with dental caries, one of the most prevalent chronic oral diseases 73 
worldwide (14, 15). Most characterised strains are clinical isolates of human origin, while 74 
some opportunistically pathogenic species such as Actinomyces israelii and Actinomyces 75 
gerecseriae are known to cause the uncommon infectious disease actinomycosis (16). 76 
Though Actinomyces spp. are abundant in the oral cavity, little is known about their presence 77 
in the gut, probably due to their low abundance (<0.1%) (10). Many Actinomyces spp. have 78 
been isolated from faecal material and from the gastrointestinal tract of different animals, 79 
indicating a propensity for gastric transit survival and their presence has also been noted in 80 
the urogenital tract (17-24). Here, we identify a new group of bacteriocins using a pan-81 
genomic in silico approach paired with functional screening. Many in silico genome mining 82 
tools have been developed for the successful detection of novel antimicrobial producing 83 
operons (25, 26). Obviously, these methods rely on relationships with previously known 84 
genes and therefore functional screening is crucial for the identification of unrelated 85 















antimicrobials. In this study we isolated a potent bacteriocin producing strain of Actinomyces 86 
ruminicola from sheep faeces – the bacteriocin produced resembled eukaryotic defensins -87 
having 3 characteristic disulphide bridges.  A subsequent pan genus Actinomyces analysis 88 
revealed that such bacteriocins are highly distributed in these bacteria albeit with a highly 89 
variable structure.  90 
Results 91 
Identification of a novel bacteriocin producing Actinomyces sp. 92 
Actinomyces ruminicola DPC 7226 was isolated from sheep faeces. During an initial 93 
screen of >10,000 colonies for bacteriocin producers, this strain was found to produce a large 94 
zone of inhibition when overlaid with an acid tolerant indicator species Lb. delbrueckii ssp. 95 
bulgaricus LMG 6901 (Fig. 1a). The neutralised cell-free supernatant (CFS) was also found 96 
to produce a zone of inhibition against Lb. delbrueckii ssp. bulgaricus LMG 6901, indicating 97 
production of a soluble antimicrobial molecule (Fig. 1b). This activity was eliminated when 98 
the supernatant was treated with 20 mg ml-1 Proteinase K, demonstrating that the 99 
antimicrobial is a peptide (data not shown).  100 
Antimicrobial activity was purified from pelleted bacterial cells (C18 SPE, Reversed 101 
phase HPLC) and CFS (Amberlite XAD, C18 SPE, Reversed phase HPLC) and MALDI-102 
TOF MS of active peaks detected a mass of 4091±1 Da (Fig. 2a, Fig. 2b). The mass could 103 
also be detected by colony MS (Fig. 2c). The activity of the HPLC purified fraction from 104 
CFS was assayed against Lb.delbrueckii ssp. bulgaricus LMG 6901and found to be active at 105 
<1 µgml-1 (Fig. 2d). The antimicrobial was found to be heat stable, retaining almost all 106 
activity after 30 mins at 100 °C, but was completely lost after treatment at 121°C for 15 mins.  107 
Spectrum of inhibition 108 















A range of indicator organisms were tested against the purified antimicrobial to 109 
determine the spectrum of inhibition. The antimicrobial was active against a broad range of 110 
genera with 22 of the 27 strains screened inhibited to varying degrees, including species of 111 
the genera Lactococcus, Enterococcus, Lactobacillus, Streptococcus, Pediococcus, Bacillus, 112 
Staphylococcus, other Actinomyces sp. and Clostridium spp (Fig. 3). No inhibition was 113 
observed against the Gram negative species Salmonella enterica or Escherichia coli. Listeria 114 
spp., and Bacillus spp. were inhibited weakly or not at all (Fig. 3). Inhibition was found 115 
against other Actinomyces sp. and activity was particularly strong against Staphylococcus 116 
aureus and Clostridium difficile.  117 
MICs were determined against E. faecium APC1031, E. faecium NCDO0942, S. 118 
aureus R693, S. agalctiae APC1055 and C. difficile DPC6534 (Supplementary Figure 1.) 119 
Enterococci were inhibited at 3.05 – 6.1 μM. S. aureus was inhibited at 3.05 μM. S. 120 
agalactiae and C. difficile were inhibited at 0.76 μM (Supplementary Figure 1.). 121 
Distribution of genes encoding bacteriocins in the genus Actinomyces  122 
 As the active mass could not be matched to any previously known antimicrobial 123 
peptide, and no antimicrobial compounds have previously been described within the species, 124 
the genome of A. ruminicola DPC 7226 was sequenced. Following genome annotation, the 125 
draft genome was analysed using BAGEL4 to search for potential antimicrobial encoding 126 
operons. Gene clusters were identified containing putative genes for thiopeptide production 127 
(data not shown) but the masses predicted, 2195.4 Da and 1152.5 Da, did not correlate with 128 
the mass detected in the antimicrobial HPLC fraction. 129 
In conjunction with screening the genome of A. ruminicola DPC 7226, we also set out 130 
to characterise the antimicrobial potential of the genus. One hundred and sixty one 131 
Actinomyces spp. genomes in various stages of assembly were screened using BAGEL4 132 















(Supplementary Table 1). The isolates were obtained from humans (78.2%), other animals 133 
(16.1%), or unknown origin (4.9%), while one was an environmental isolate (0.6%). One 134 
hundred and six areas of interest were revealed in 76 strains, covering 18 species. Ninety 135 
areas of interest contained complete operons for antimicrobial production. Twenty nine were 136 
predicted to be class I bacteriocins, including 7 LanBC modified lantibiotics, Sixteen LanM 137 
modified lantibiotics, one single-peptide sactibiotic, three lasso peptides, and two thiopeptide 138 
producing operons were also detected. Thirteen operons were predicted to encode class II d 139 
bacteriocins and a further 48 operons were predicted to encode bacteriolysins. A phylogenetic 140 
tree was generated from the 16S rRNA sequences of 142 Actinomyces with Bacteroides 141 
fragilis ATCC 25285 as the root, and overlaid with operon type and strain source (Fig. 4). 142 
Bacteriocin production was widely distributed across the Actinomyces pangenome, though 143 
bacteriolysin production was found exclusively among human isolates (Fig. 4).  144 
Genetic and molecular characterization of the actifensin determinant 145 
To identify the gene encoding the 4091±1 Da peptide within the genome of A. 146 
ruminicola DPC 7226, pure peptide was subjected to N-terminal sequencing which revealed a 147 
primary sequence consisting of Gly-Phe-Gly-X-Asn-Leu-Ile-Thr-Ser-Asn-Pro-Tyr-Glu-X-148 
Ser, with blanks at residue positions 4 and 14 denoted as probable cysteines (Fig. 5a). This 15 149 
amino acid sequence could be matched to a 69 residue small open reading frame in the draft 150 
genome, capable of encoding a 37 amino acid mature peptide (hereafter referred to as 151 
actifensin)  with a predicted mass of 4097.7 Da preceded by a 32 residue leader sequence 152 
(Fig. 5a). 153 
The genetic locus encoding actifensin is shown in Fig. 5b, where afnA encodes 154 
actifensin. Within an approximately 6.5 kbp upstream region of afnA, genes encoding an 155 
ABC transporter permease (afnJ), an ATP binding ABC transporter (afnK) and another ABC 156 















transporter permease (afnL) were identified as being present. Downstream of afnA three 157 
hypothetical genes of unknown function (afnG - afnI) were found, followed by genes 158 
encoding another ATP binding ABC transporter (afnF), a predicted α/β hydrolase 159 
superfamily protein (afnE) another protein of unknown function, a subtilisin like protease and 160 
a LuxR family transcription factor (afnD, afnC, and afnB respectively). Within afnE is a 161 
predicted RHO-independent transcription terminator, and upstream of the structural gene are 162 
four predicted promoters. A putative ribosome binding site was also identified nine base pairs 163 
upstream of the ATG start codon for the peptide consisting of a purine rich sequence 5’ – 164 
GAAAGG – 3’ (Fig. 5a). 165 
The leaderless structural peptide was found to have a predicted mass of 4097.7 Da. 166 
This mass was 6 Da higher than detected by MALDI-TOF MS. The difference between 167 
predicted and observed masses most likely corresponds to the loss of 6 hydrogen atoms 168 
during the formation of disulphide bonds between the six cysteines. Short peptides with 169 
numerous disulphides in specific positions are characteristic of the defensin peptide families 170 
(4). To confirm the presence of disulphide bonds in actifensin, pure peptide was reduced and 171 
alkylated to break open the disulphide bonds and then subjected to trypsin digestion and 172 
peptide mass fingerprint analysis by MALDI-TOF MS. Reduction and alkylation of 173 
actifensin resulted in a 4440 Da mass which correlates with the expected increase in mass of 174 
58 Da for each cysteine. MALDI TOF MS analysis of the subsequent trypsin digest detected 175 
a mass of 2257.02 Da which corresponds to the first 19 amino acids of the peptide (Gly-1 to 176 
Lys-19) containing three alkylated cysteine residues. Three other predicted masses, Ser-20 to 177 
Arg-24, Gly-25 to Arg-31, and Thr-32 to Tyr-37 (predicted mass and alkylated masses 178 
581.30 Da, 584.25 Da, and 803.31 Da respectively) were not detected.  179 
Discovery of actifensin homologs 180 















BLASTp analysis with AfnA found homologous ORFs within the fungal genera 181 
Blastomyces, Emmonsia, and Emergomyces, Helicocarpus griseus, and a defensin from the 182 
mollusc species Rhuditapes philippinarum (58%, 58%, 55%, 52%, and 61% identity, 183 
respectively, Supplementary Figure 2). Characteristic conserved cysteines were noted though 184 
low sequence identity was observed between the mature actifensin peptide and eukaryotic 185 
defensins. The same was found when AfnA was compared with known previously 186 
characterised arthropod, ascomycete and mollusc defensins (Fig. 6a) which conserved 187 
secondary structures (Fig. 6b). BLASTp analysis using the 69 residue AfnA sequence 188 
identified 37 homologous structural genes within the genus Actinomyces and one homolog 189 
from a Corynebacterium sp. sequence (Fig. 6a). Further analysis indicated that the homologs 190 
were present in 15 operons from 14 strains, in addition to conserved genes for transport, 191 
transcription regulation, and proteolytic activity (Fig. 6b). Actinomyces sp. 2119, A. oris 192 
S64C, A. succiniciruminis AM4, A. oris CCUG34286, Actinomyces sp. F0337, Actinomyces 193 
sp. HMSC075C01, and A. oris MMRCO6-1 had at least two actifensin homologs, while 194 
Actinomyces sp. F0337 containing an operon with seven copies, the most observed within one 195 
genome, (Fig. 7b). The genome of A. oris MMRCO6-1 contained six encoded actifensin 196 
homologs detectable over two contigs but only one (contig 50) contained the other conserved 197 
ORFs (afnB-I, J-K) present in the actifensin operon. Twelve of 14 operons had a highly 198 
conserved arrangement of afnB-I, all of which also had ABC transporter genes directly 199 
upstream of the bacteriocin ORF. The mean amino acid identity between all structural genes 200 
was 52%. The highest identity observed between actifensin and a homolog was 77% identity 201 
with afnA in Actinomyces sp. CTC72, though higher identities were observed between other 202 
peptides (Supplementary Fig. 3). We proceeded to characterise ten predicted cysteine-203 
stabilised αβ (CSαβ) peptides predicted by Dash et al. (2019). The peptides are present in five 204 
Actinomyces genomes bringing the total number of peptides to 47 homologous structural 205 















genes in 19 strains  Actinomyces oris S24-V, Actinomyces denticolens PA, Actinmoyces sp. 206 
Chiba-101, Actinomyces johnsonii F0542 and Actinomyces sp. F0330,  have genes which 207 
were not identified using BLASTp and the actifensin propeptide sequence (27).   S24-V, PA, 208 
and Chiba-101 display the conserved afnB to afnI ORFs following afnA, which is absent in 209 
strains F0330 and F0542 (Fig. 7b). 210 
The propeptide contains a conserved G-X-E motif prior to the start of the mature 211 
peptide (Fig. 7a). In 36 of the peptides, an alanine residue is present after the glycine which 212 
may be involved in secretion and cleavage. This putative GA cleavage signal is replaced by a 213 
TS motif in eight of the 49 peptides (A. oris S64C afnA5, A. oris CCUG34286 afnA7, A. oris 214 
MMRCO6-1 contig 75 afnA2, Actinomyces sp. F0337 afnA4, Actinomyces sp. HMSC075C01 215 
afnA4, A. oris MMRCO6-1 contig 50 afnA4, afnA3 and A. oris S24V afnA5). A conserved 216 
Pro residue was noted following the first conserved Cys in addition to a conserved G-Y-X-G-217 
G-X-C sequence at positions 56-62 of the propeptide (22-28 in the active peptide, Fig. 7a).  218 
Discussion 219 
We describe a novel group of bacteriocins with broad spectrum inhibitory activity 220 
within the Actinomyces genus. Actifensin is the first such bacteriocin to be discovered which 221 
is produced by a strain of Actinomyces ruminicola. 222 
Actifensin inhibited a broad range of Gram-positive species including notable 223 
pathogens such as vancomycin-resistant Enterococcus and methicillin-resistant 224 
Staphylococcus. Given the global challenge of the increase in antibiotic resistance there is an 225 
urgent need for new classes of antimicrobials. Bacteriocins have been suggested as an 226 
alternative to conventional antibiotics due to their effectiveness at low concentrations and 227 
their potential to be genetically modified [2]. Class II bacteriocins are diverse in sequence 228 















and structure, whose mechanism of action is through interaction with the cell membrane, 229 
causing permeabilization, pore formation and dissipating membrane potential [31]. The 230 
defensin-like bacteriocin laterosporulin10 has been found to act on the cell membrane of S. 231 
aureus Mtb H37Rv, disrupting cellular homeostasis [7]. Plectasin and eurocin, fungal C6 232 
defensins are known to bind lipid II, inhibiting bacterial cell wall biosynthesis [32, 33]. 233 
Actifensin possesses an N-terminal loop extension which in other defensin peptides has been 234 
implicated in membrane disruptive capability (28). The loop consists of nine residues 235 
between Cys-4 and Cys-14 beginning with an Asn. In most of the other peptide sequences 236 
identified, the N-loop is six residues long, beginning with a Pro, (excepting afnA from 237 
Actinomyces sp. F0588, and A. naeslundii S44D which have an eight residue N-loop with a 238 
serine or arginine in the first position respectively, followed by a Pro. (Fig. 7a).  239 
Actifensin also inhibited the growth of C. difficile and C. sporogenes. Clostridia are 240 
known colonizers of the rumen [37, 38], and as A. ruminicola DPC7226 was isolated from 241 
the faeces of a ruminant, actifensin production may provide a competitive advantage in the 242 
gut microbiome.  Actinomyces neuii and Actinomyces radingae were both inhibited by 243 
actifensin, however, it would be interesting to see if cross resistance between actifensin and 244 
other actifensin-like producers exists. 245 
A pan genus in silico screen revealed that the genus Actinomyces (Fig. 4) are a rich 246 
source of antimicrobials and  have genes for bacteriolysin and lantibiotic production (48/90, 247 
and 29/90 operons respectively). Thirteen class II bacteriocins were predicted by BAGEL, 248 
but neither the actifensin operon, nor its homologs were detected due to lack of similarlarity 249 
with known systems. One previous study described odontolycin, a bacteriocin produced by an 250 
Actinomyces odontolyticus dental plaque isolate, though no further research on the peptide 251 
was reported (29). Interestingly in our study no operons for bacteriocin production were 252 
found among five A. odontolyticus genomes screened (Fig. 4). 253 















The actifensin structural gene comprises of a 37 amino acid mature peptide preceded 254 
by a 32 amino acid leader sequence (Fig. 5). A GA motif at positions -3 and -2 was 255 
identified, which is a known cleavage signal used in ABC transporter mediated secretion 256 
[29]. Indeed, there are a number of predicted ABC transporter genes within the actifensin 257 
operon. ABC transporter genes could also play a role in self-immunity to the actifensin 258 
peptide. Unusually, an additional glutamic acid residue is present at -1 before the mature 259 
peptide. As the purified peptide was subjected to N-terminal sequencing, we can be certain 260 
that the mature peptide begins with a glycine residue, therefore the additional glutamic acid 261 
residue at -1 is most likely subject to exopeptidase cleavage prior to activity, and indeed there 262 
are genes present with predicted protease activities (Fig. 5).  263 
The GA cleavage motif is present in 36 of the homolog structural genes, with TS 264 
replacing the motif in eight instances, GT and GG in two cases, and GS SA, and DA in one 265 
each (Fig. 7a). A double glycine is the most commonly found motif for ABC transporter 266 
mediated cleavage among bacteriocins, though GA and GS have also been observed [29]. It 267 
will be interesting to see if the peptides bearing other residues at this location are indeed 268 
subject to ABC-mediated transport. We note that each operon containing a gene with a non-269 
traditional TS/GT/SA/DA signal contains at least one more structural gene than those with a 270 
GG/GA sequence. This could indicate potential diversification of a repertoire of bacteriocins 271 
enabling improved ability to combat multiple competitors. It was also surprising that an 272 
actifiensin homolg was found in a distantly related Corynebacterium sp., though many of the 273 
conserved genes in the Actinomyces spp. operons were not present (Fig. 7b). As such this 274 
may be non-functional as ABC transporter related genes are missing upstream of the 275 
structural gene and the conserved afnB - afnI pattern is absent. The genera Corynebacterium 276 
and Actinomyces are distantly related members within the phylum Actinobacteria and some 277 
species are known members of plaque biofilms, providing an opportunity for horizontal gene 278 















transfer [16], though given the dissimilarity of the operons, they may have been acquired 279 
independently at some stage. 280 
As stated above, the laterosporulins produced by Brevibacillus sp. are two structurally 281 
defensin-like bacteriocins with broad spectrum inhibitory activity [6, 7]. They are 57.6% 282 
similar in amino acid sequence to each other which is comparable to actifensin and its 283 
predicted homologs but share the conserved cysteine residues which form disulphide bridges. 284 
Conserved disulphides are characteristic of defensins and are present in vertebrate, 285 
invertebrate, plant, fungal defensins, and defensin like peptides [4]. Actifensin has a predicted 286 
mass of 4097.7 Da but the actual mass is 4091±1 Da by MALDI-TOF MS. The same 287 
discrepancy in predicted and observed mass was noted with laterosporulin, where six 288 
hydrogen atoms are lost in the formation of disulphide bonds. We hypothesize that bonds in 289 
actifensin likely form in the 1-4, 2-5, 3-6 formation similar to ascomycete and arthropodC6 290 
defensins (Fig. 6), as the amino acid motifs (C-X[5-12]-C-X[3]-C-X[9-10]-C-X[4-5]-C-X-C) 291 
are conserved [5] The structure of laterosporulin10 has been determined to be architecturally 292 
similar in structure to human α-defensin though its disulphide connectivity is homologous to 293 
that of β-defensins (Fig. 8) [30]. The overall architecture and disulphide connectivity of 294 
actifensin is likely to be homologous to that of C6 defensins consisting of an N-terminal α-295 
helix followed by a two-stranded antiparallel beta sheet-stabilized by disulphide bridges (Fig. 296 
8). Interestingly an actifensin homolog we identify as afnA from Actinomyces sp. oral taxon 297 
171 str F0337 has had its 3D structure determined and is publicly available from an online 298 
database. The peptide labelled actinomycesin is strikingly similar to C6 fungal and arthropod 299 
defensins which have also been characterised  (Fig. 6), however no published material is 300 
available regarding its activity, antmicrobial or otherwise. Indeed, two antiparallel beta-sheets 301 
stabilised by disulphide bonds with an interposed short turn region, previously described as 302 















the γ-core motif, are a ubiquitous feature of antimicrobial peptides (30). Actifensin exhibits 303 
the highly conserved GXC (positions 26-28 in the mature peptide) as do all of its homologs.  304 
CSαβ peptides comprise one of the most widespread families of defensins, and 305 
defensin-like peptides. A recent publication identified a number of CSαβ sequences in 306 
bacterial genomes with potential for antimicrobial, toxin, or signalling activity (27). Of 58 307 
peptides identified within the phylum Actinobacteria  by Dash et al. (2019), 34 were of the 308 
genus Actinomyces, 24 of which we identified using BLAST with the actifensin propeptide 309 
sequence (Supplementary Table 2). A further 113 bacterial peptide sequences identified by 310 
Dash et al. remain to be characterised from a functional perspective and could be a potent 311 
source for future antimicrobials. Interestingly a bacterial defensin-like peptide AdDLP  312 
identified in silico was synthesised and recombinantly expressed, and the peptide was found 313 
to have anti-Plasmodium activity (31). The bacterial CSαβ peptides could be an untapped 314 
source of potential applications, and have been proposed as the ancestral evolutionary origin 315 
of eukaryotic defensins (32).  316 
In the search for novel antimicrobials for application in health and food, genomic and 317 
pangenomic approaches are becoming increasingly common [3, 4]. These approaches are 318 
advantageous in that large amounts of genetic data can be analysed to identify novel 319 
antimicrobials/bacteriocins, and can even allow one to ‘reincarnate’ otherwise ‘dormant’ 320 
genes [5]. However, such analyses are dependent on the ability of programs to predict based 321 
on databases of previously identified sequences, and so peptides with novel structures and 322 
operons may not be detected. Though a number of bacteriocin operons were found in the 323 
Actinomyces spp. genomes using BAGEL, actifensin was not identified by genome sequence 324 
alone, which highlights the importance of functional screening for antimicrobial compounds 325 
in addition to in silico screening. Using BLAST thirty-seven structural genes with homology 326 
to actifensin were found in Actinomyces spp., and a single structural gene from a 327 















Corynebacterium sp. As some CSαβ peptides function as toxins future applications will 328 
require any potential cytotoxic effects to be assayed. We propose that actifensins and the 329 
laterosporulins may constitute a new subgroup of class II bacteriocins; the defensin-like 330 
bacteriocins. These bacteriocins share only moderate identity to each other but do contain 331 
highly conserved cysteine residues and are structurally related to eukaryotic defensins.  332 
Conclusions 333 
 A series of novel defensin-like bacteriocins  within the genus Actinomyces were identified 334 
using an in silico pan-genomic approach coupled with a functional screen, many of which are 335 
ubiquitous members of the oral microbiome. The bacteriocins represent a potential new class 336 
of antimicrobial peptides, defensin-like bacteriocins which may have widespread applications 337 
as antimicrobials in food and human health.  338 
Experimental Procedures 339 
Isolation of bacteria and identification of bacteriocin production  340 
Samples of raw milk, unpasteurised cheeses, sheep faeces and honey were serially 341 
diluted in maximum recovery diluent (Oxoid) and plated on several media types for the 342 
isolation of bacteriocin producing bacteria; Streptococcus thermophilus selective agar 343 
(tryptone 10.0 gL-1, sucrose 10.0 gL-1, yeast extract 5.0 gL-1, K2HPO4 2.0 gL-1, bromocresol 344 
purple 0.03 gL-1, agar 15.0 gL-1) incubated aerobically at 42 °C; M17 (Merck) supplemented 345 
with 10% w/v lactose incubated at 30 °C aerobically; de Man, Rogosa, and Sharpe (MRS, 346 
Difco) agar supplemented with 30 µgmL-1 L-vancomycin hydrochloride incubated at 37 °C; 347 
MRS adjusted to pH 5.4 incubated at 42°C anaerobically; Lactobacillus selective agar (LBS, 348 















supplier) incubated at 30 °C anaerobically; and TOS (Transgalactosylated oligosaccharide) 349 
agar supplemented with 50 µgmL-1 lithium mupirocin incubated at 37 °C anaerobically. 350 
Isolates were subject to an initial bacteriocin production screen by overlaying with 10 351 
mL ‘sloppy’ MRS agar (7.5 gL-1 agar) tempered to 50 °C and seeded with an overnight 352 
culture of Lactobacillus delbrueckii ssp. bulgaricus LMG6901 (0.25% v/v). Cultures which 353 
were found to produce distinct zones of inhibition in the agar overlay were cultured in broth 354 
for well diffusion assays. For well diffusion assays, 20 mL of ‘sloppy’ MRS agar seeded with 355 
L. bulgaricus LMG6901 as before, was poured and allowed to set in which 6 mm wide wells 356 
were then bored. 50 µL of cell-free supernatant was added to each well and plates were 357 
incubated at 37 °C overnight. Zones of inhibition were indicative of antimicrobial activity.  358 
Bacterial Strains, media, reagents 359 
Strains used in this study and their incubation conditions are listed in Supplementary 360 
Table 3.  A. ruminicola DPC 7226 was routinely maintained on BHI (Oxoid) anaerobically at 361 
37 °C. Media reagents were sourced from Sigma-Aldrich (Wicklow, Ireland) unless stated 362 
otherwise.  363 
 364 
Purification of actifensin 365 
A. ruminicola DPC 7226 was grown anaerobically, statically at 37 °C in 500 mL 366 
volumes of BHI broth for 48 h. Following centrifugation, cell-free supernatant was applied to 367 
an Econo column containing 30 g Amberlite XAD beads prewashed with Milli Q water. The 368 
column was washed with 300 mL 30% ethanol and 300 mL 2-propanol 0.1% TFA (IPA). IPA 369 
was removed by rotary evaporation and the sample was applied to a 60 mL, 10 g Strata–E 370 















C18 SPE column (Phenomenex, Cheshire, UK) pre-equilibrated with methanol and water. 371 
The column was washed with 60 mL 25% ethanol and then 60 mL IPA. 372 
 Centrifuged cells were combined with 100 mL IPA and stirred at room temperature 373 
for 3-4 h. The resulting suspension was centrifuged and the cell extract and purified CFS 374 
were assayed by MALDI TOF mass spectrometry to determine the molecular mass of 375 
antimicrobial compounds (Axima TOF2 MALDI-TOF mass spectrometer, Shimadzu Biotech, 376 
Manchester, UK). A MALDI target plate was precoated with CHCA matrix solution, 0.5 µl 377 
of the supernatant from the cell extract was then placed on the target and a final layer of 378 
matrix solution was added. Positive-ion linear or reflectron mode was used to detect peptide 379 
masses. 380 
Actifensin characterisation 381 
Characterisation was performed using purified bacteriocin. To test protease 382 
susceptibility 100 µL aliquots of 50 µgmL-1 were subjected to treatment with 10 mgmL-1 383 
proteinase K (Sigma-Aldrich) and α-chymotrypsin (Sigma-Aldrich) at 37 °C for 3h, followed 384 
by a 10 min incubation at 100 °C to denature the enzymes. 50 µL aliquots were assayed on L. 385 
delbrueckii ssp. bulgaricus LMG6901 indicator plates. Heat stability was determined by 30 386 
min incubations at 60, 70, 80, 90, 100 °C and by autoclaving at 121 °C for 15 min. 387 
For spectrum of activity, a well diffusion assay was carried out as described above 388 
with the strains in in the appropriate medium. 50 µL of purified bacteriocin at a concentration 389 
of 50 µgmL-1 was added to a well. Following overnight incubation under the appropriate 390 
conditions zones of activity were measured and categorised as no inhibition, weak inhibition 391 
(0.5 mm – 2 mm), strong inhibition(2.5 mm – 5 mm), and very strong inhibition (>5 mm) 392 
(Table 1). Minimum inhibitory concentration against selected pathogens was assayed as 393 
above, starting at 100 µgmL-1 peptide solution serially diluted 1:2 to 0.78 µgmL-1. 394 















Draft genome sequencing 395 
DNA was extracted using a GenElute bacterial genomic DNA kit (Sigma) and 396 
prepared for sequencing using a Nextera XT kit (Illumina) for library preparation. DNA was 397 
quantified using a Qubit 2.0 fluorometer. Sequencing was carried out using an Illumina 398 
MiSeq platform with paired-end 2 x 300 base pair reads by the Teagasc Sequencing Centre, 399 
Teagasc Food Research Centre Moorepark. Assembly was performed using tools available on 400 
the public server from usegalaxy.org (33). Assembly was performed de novo using SPADES 401 
(version 3.0.0) and resulted in 116 contigs. Contigs were aligned to a reference genome using 402 
Mauve (version 20150226 build 10), followed by annotation with RAST (version 2.0). The 403 
annotated genome was analysed for predicted bacteriocin and secondary metabolite 404 
production clusters using BAGEL4 (34), and any further annotation was carried out using 405 
Artemis genome browser (version 16.0.0). Genomic data are available from GenBank/EMBL 406 
under accession no. SPKK00000000.  407 
BAGEL screen and phylogenetic analysis of Actinomyces species 408 
Genbank and fasta assemblies of the genus Actinomyces were acquired from the NCBI 409 
assembly database and screened using BAGEL4 (35). Where available corresponding 16S 410 
rRNA sequences were acquired from the RDP database (36) and where unavailable 411 
Actinomyces spp. genomes were subject to analysis using RNAmmer (37). 16S rRNA 412 
sequences were aligned using MUSCLE (38, 39) and a phylogram was generated using iTOL 413 
(40). The phylogram was then overlaid with the BAGEL screen data. 414 
Reverse bacteriocin identification, peptide and structure prediction and homology 415 
Two hundred µg freeze-dried purified peptide was sent for N-terminal amino acid 416 
sequencing (AltaBioscience, UK). The resulting 15 residue sequence, 417 















GFGXNLITSNPYQXS, was used to search for a bacteriocin structural gene with Artemis 418 
genome browser. Following identification of the structural gene, other genomes were 419 
searched for genes homologous to the active and pro-peptide using BLASTp, genes on 420 
contigs consisting of less than 5 kbp were excluded. Additional actifensin homologs were 421 
identified from Dash et al. (2019) among 147 non-redundant bacterial CSαβ peptide 422 
sequences (27).  Alignments were generated using Clustal Omega (41), and visualised with 423 
Jalview (42). Structural modelling was performed using SWISSMODEL (43) online software 424 
and structural images were generated using PyMOL (44).  425 
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Figure 1: Antimicrobial activity of  Actinomyces ruminicola DPC 7226 from (a) colonies 569 
overlaid with L. delbrueckii ssp. bulgaricus LMG6901in sloppy MRS (b) and in well 570 
diffusion with neutralised CFS.  571 
Figure 2: Detection of actifensin 4091 Da +/_ 1 Da (indicated by arrows), by MALDI-TOF 572 
MS from (a) cell free supernatant, (b) cell extract, (c) colonies on a plate. (d) The 4091±1 573 
compound when purified was active to <1 µgmL-1, indicator L. bulgaricus LMG 6901. 574 
Figure 3: Inhibition of actifensin against a broad spectrum of indicator species. Weak 575 
inhibition, 0.5 - 3 mm zone, strong inhibition, 3 – 5 mm zone, very strong inhibition > 5 mm 576 
zone. *Vancomycin-resistant Enterococcus, +Methicillin-resistant Staphylococcus aureus. 577 
Figure 4: Phylogram of Actinomyces genomes using 16Sssequences overlaid with BAGEL4 578 
predictions, strain source and presence of actifensin or predicted homolog operon.  579 
Figure 5: (a) 69 residue pro-peptide identified following genome analysis using the 15 amino 580 
acid sequence (underlined) determined by N-terminal amino acid sequencing, Putative 581 
ribosome binding site highlighted 8 base pairs upstream of start codon. (b) Genetic vicinity of 582 
structural gene containing nearby genes for transport, hypothetical, proteolytic proteins, and a 583 
transcription factor.  584 
Figure 6: (a) Mature peptide sequence alignment of afnA with characterised defensin family 585 
peptides from different phyla. Known disulphide connectivities outlined above highlighted 586 
cysteine residues. (b)Available 3-D structures of  above sequences. Alpha-helices coloured 587 
red, beta-sheets shown in blue. Protein data bank accession numbers shown below in 588 
brackets. 589 
Figure 7: (a) Sequence alignment of actifensin propeptide sequence (boxed) with structural 590 
genes predicted Actinomyces spp. peptides. Amino acids with greater than 80% conservation 591 















are coloured, leader sequence and mature active peptide are highlighted above. Putative 592 
disulphide connectivity between conserved cysteines of the mature peptide are indicated 593 
below, right and putative cleavage site is indicated below, centre. (b) Diagram of actifensin 594 
homolog production operons. Multiple bacteriocin genes within one operon are denoted 595 
afnA1 – afnA7 where present.  596 
Figure 8; Conserved structures of the defensin peptide superfamily and defensin-like 597 
bacteriocins, laterosporulin and actifensin. β-sheets coloured blue, α-helices coloured red, 598 
disulphide bonds shown in yellow. 599 
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